tiprankstipranks
Advertisement
Advertisement

PCVX Stock Latest News

Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline
Company AnnouncementsVaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline
32s ago
8K
PCVX
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
PremiumThe Fly
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
2h ago
PFE
PCVX
Vaxcyte narrows previously communicated VAX-31 guidance
PremiumThe Fly
Vaxcyte narrows previously communicated VAX-31 guidance
2h ago
PCVX
Analyst Reiterates Buy Rating and Maintains $110 Price Target on Robust Vaccine Pipeline and Upcoming Clinical Catalysts
PremiumRatings
Analyst Reiterates Buy Rating and Maintains $110 Price Target on Robust Vaccine Pipeline and Upcoming Clinical Catalysts
28d ago
PCVX
Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)
PremiumThe Fly
Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)
29d ago
PCVX
Vaxcyte Announces Board Transition and New Director Appointment
PremiumCompany AnnouncementsVaxcyte Announces Board Transition and New Director Appointment
2M ago
8K
PCVX
Vaxcyte Shareholders Reelect Directors, Approve Governance Measures
Premium
Company Announcements
Vaxcyte Shareholders Reelect Directors, Approve Governance Measures
3M ago
8K
PCVX
Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines
Premium
Company Announcements
Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines
3M ago
PCVX
Vaxcyte doses first participant in VAX-A1 study
PremiumThe Fly
Vaxcyte doses first participant in VAX-A1 study
3M ago
PCVX
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
PremiumThe Fly
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
4M ago
PCVX
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
PremiumThe Fly
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
5M ago
PCVX
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
PremiumThe Fly
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
6M ago
PCVX
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
PremiumCompany AnnouncementsVaxcyte Earnings Call: Cash Strength, Trials Accelerate
6M ago
PCVX
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
Premium
Company Announcements
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
6M ago
PCVX
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
Premium
Ratings
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
6M ago
PCVX
Vaxcyte price target raised to $89 from $85 at BTIG
PremiumThe Fly
Vaxcyte price target raised to $89 from $85 at BTIG
6M ago
PCVX
Vaxcyte price target lowered to $133 from $134 at BofA
PremiumThe Fly
Vaxcyte price target lowered to $133 from $134 at BofA
6M ago
PCVX
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
PremiumThe Fly
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
6M ago
PCVX
Vaxcyte price target raised to $75 from $50 at TD Cowen
PremiumThe Fly
Vaxcyte price target raised to $75 from $50 at TD Cowen
6M ago
PCVX
Vaxcyte Launches New $500 Million ATM Equity Program
PremiumCompany AnnouncementsVaxcyte Launches New $500 Million ATM Equity Program
6M ago
8K
PCVX
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
Premium
The Fly
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
6M ago
PCVX
Is PCVX a Buy, Before Earnings?
Premium
Pre-Earnings
Is PCVX a Buy, Before Earnings?
6M ago
PCVX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >